GILD vs. AMGN, SGEN, BIIB, MRNA, ARGX, BNTX, VRTX, REGN, ELV, and CI
Should you be buying Gilead Sciences stock or one of its competitors? The main competitors of Gilead Sciences include Amgen (AMGN), Seagen (SGEN), Biogen (BIIB), Moderna (MRNA), argenx (ARGX), BioNTech (BNTX), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Elevance Health (ELV), and The Cigna Group (CI). These companies are all part of the "medical" sector.
Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.
Amgen has lower revenue, but higher earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Gilead Sciences pays an annual dividend of $3.00 per share and has a dividend yield of 4.0%. Amgen pays an annual dividend of $8.52 per share and has a dividend yield of 3.2%. Gilead Sciences pays out 69.0% of its earnings in the form of a dividend. Amgen pays out 57.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Gilead Sciences currently has a consensus price target of $90.05, suggesting a potential upside of 19.09%. Amgen has a consensus price target of $265.44, suggesting a potential downside of 0.85%. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Gilead Sciences is more favorable than Amgen.
In the previous week, Amgen had 10 more articles in the media than Gilead Sciences. MarketBeat recorded 21 mentions for Amgen and 11 mentions for Gilead Sciences. Amgen's average media sentiment score of 0.92 beat Gilead Sciences' score of 0.82 indicating that Amgen is being referred to more favorably in the news media.
Amgen has a net margin of 30.02% compared to Gilead Sciences' net margin of 20.03%. Amgen's return on equity of 196.60% beat Gilead Sciences' return on equity.
82.3% of Gilead Sciences shares are owned by institutional investors. Comparatively, 74.4% of Amgen shares are owned by institutional investors. 0.2% of Gilead Sciences shares are owned by company insiders. Comparatively, 0.6% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Gilead Sciences has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.
Gilead Sciences received 942 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 77.74% of users gave Gilead Sciences an outperform vote while only 72.80% of users gave Amgen an outperform vote.
Summary
Amgen beats Gilead Sciences on 11 of the 20 factors compared between the two stocks.
Get Gilead Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Gilead Sciences Competitors List
Related Companies and Tools